- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Bevacizumab, Pertuzumab, Sandostatin LAR® Depot
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2209–2232
of 2,670
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoporosis
- Interventions
- Alendronate
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Covid19
- Interventions
- Alvelestat, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pain, Obesity, Sedentary Behavior
- Interventions
- MORPH
- Behavioral
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Transfemoral Amputation
- Interventions
- Active knee (Ossur Power Knee II), Adaptive knee (Ossur Rheo), Passive knee (Various manufacturers)
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Desmoid Fibromatosis
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Sorafenib Tosylate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Arroyo Grande, California + 79 more
- Conditions
- Breast Cancer, Fatigue, Hypothyroidism
- Interventions
- physiologic testing, fatigue assessment and management, management of therapy complications
- Other · Procedure
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 20 Years to 80 Years · Female only
- Enrollment
- 541 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
- Conditions
- Macular Degeneration
- Interventions
- Bevasiranib
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
- Conditions
- COVID-19
- Interventions
- BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
- Conditions
- Critical Limb Ischemia
- Interventions
- JVS-100(4 mg) or placebo/8 injections, JVS-100(8 mg) or placebo/8 injections, JVS-100(8 mg) or placebo/16 injections, JVS-100(16 mg) or placebo/16 injections
- Biological
- Lead sponsor
- Juventas Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Minneapolis, Minnesota + 2 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- TAK-442, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
- Conditions
- Breast Neoplasms
- Interventions
- Ipatasertib, Paclitaxel, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 17
- States / cities
- Fullerton, California • Los Angeles, California • Santa Monica, California + 13 more
- Conditions
- Barrett Esophagus, Esophageal Cancer
- Interventions
- metformin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Hines, Illinois • Rochester, Minnesota • Cleveland, Ohio + 1 more
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Ondansetron, Vestipitant
- Drug
- Lead sponsor
- Accenture
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 3 more
- Conditions
- Frail Older Adults
- Interventions
- Progressive Multi-Component Intervention, Usual Care
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Glenside, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Orange, California • Atlanta, Georgia + 3 more
- Conditions
- Prostheses, Upper Limb Amputation Below Elbow
- Interventions
- ASTERISK System, Wired Configuration
- Device
- Lead sponsor
- Liberating Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Holliston, Massachusetts
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Obatoclax, Carboplatin/etoposide
- Drug
- Lead sponsor
- Gemin X
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
- Conditions
- COPD
- Interventions
- AQX-1125, Placebo
- Drug
- Lead sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Northridge, California • Palm Springs, California + 15 more
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 148
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more
- Conditions
- Type II Diabetes Mellitus
- Interventions
- JTT-130, JTT-130 Placebo
- Drug
- Lead sponsor
- Shionogi Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Scottsboro, Alabama + 45 more